entertainment -WSS

entertainment

author：Wikipedia 2025-09-27 16:50:21 - browse：4354

Two people run on the sugar-phosphate backbone of DNA while holding base pairs — in the lab coverage from STAT — Adobe

LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies have opened the door to treating many more inherited conditions than previously possible. A few recent cases, in which bespoke medicines were created for children with exceedingly rare mutations, have raised hopes for furthering the approach.

Now, researchers and government agencies in the U.K. are trying to figure out the nitty-gritty to replicate those early one-off successes for as many patients as possible — what sort of preclinical testing a tailor-made treatment needs to go through before being used, what regulatory thresholds each treatment needs to clear, and how to pay for these therapies.

“A lot of the barriers are no longer scientific — we can make these drugs,” said Matthew Wood, a professor of pediatrics at the University of Oxford. “It’s more about, can we make them at a cost that is reasonable enough? And can we get the regulators to reduce the barriers to doing this so that when a patient shows up, you can actually make a drug quickly enough to benefit that patient, rather than it costing huge amounts of money and taking two or three years to do it?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Congress considering partial increase for doctor pay in Medicare

leisure time

WSS

Congress must protect the remaining independent doctors

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

'CMA Fest' 2023: How to watch, who is performing and more

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Caribou posts encouraging results on off

Websites selling Wegovy, Zepbound ingredients targeted by FDA

entertainment

entertainment

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

US jobless claims fall again as labor market continues to flash strength

Moonlake's readout produced a cash windfall. Risks remain

Why don't Americans have at

Malaria cases in Florida and Texas: Here’s what you need to know

A new ‘biological computer' targets cancer while sparing healthy cells

Walensky prepares to leave CDC — and Congress — behind

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Drug repurposing or repositioning? The language matters

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

focus

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Study gives hint on South Asians’ higher risk of cardiovascular disease

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Artificial intelligence use in health care faces greater scrutiny in 2024

AMAs digital advisors table RPM coding reform proposal, again

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

entertainment

hotspot

leisure time

focus